Several studies on the problem of management patients with chronic tonsillitis during periods of remission and exacerbation

Increase in the number of acute and chronic diseases is a global trend. On the one hand, the emergence of new types of viruses, their active mutation, an increase in antibiotic-resistant bacterial strains, a high frequency of immunodeficiency and allergic diseases contribute to this. On the other hand is inadequate treatment of inflammatory diseases of the upper respiratory tract, widespread use of systemic antibiotics without indications. The use of bioregulatory medicines with proven efficacy in the complex treatment can reduce the drug load on the body, reduce the bacterial complications and side effects. Traumeel®S joins the physiological course of inflammation and activates pro-resolving mediators, contributes to its faster completion and tissue repair. The efficacy and safety of Traumeel®S has been confirmed in many randomized clinical trials. The drug has proven its value in almost any inflammatory pathology of the upper respiratory tract and ear. The drug Lymphomyosot®, a multicomponent agent with lymphatic drainage action, has proven itself perfectly in the complex therapy of chronic tonsillitis. In November 2019, the Council of Experts of the National Medical Association of Otorhinolaryngologists on the problems of pathology of the lympharyngeal ring was held. It is recommended to use the multicomponent bioregulatory preparation Traumeel®S to correct the inflammatory process, which has shown in studies a modulating effect on inflammatory mediators without suppressing COX-2 (prostaglandins). With exacerbation of chronic tonsillitis and lymphadenitis of nonspecific etiology, it is possible to use the multicomponent preparation Lymphomyosot®, which helps to improve the drainage and detoxification function of the lymphatic system.

1. Krivopalov A.A., Ryazantsev S.V., Shatalov V.A., Shervashidze S.V. Аcute rhinitis: new therapeutic possibilities. Meditsinskiy sovet = Medical Council. 2017;(8):18–23. (In Russ.) doi: 10.21518/2079-701X-2017-8-18-23.

2. Kryukov A.I., Gurov A.V., Yushkina M.A., Izotova G.N., Sokolov S.S. Peculiarities of antibacterial therapy of purulent and inflammatory pathology of ent-organs. Meditsinskiy sovet = Medical Council. 2016;(18):18–22. (In Russ.) doi: 10.21518/2079-701X-2016-18-18-22.

3. Esposito S., Bosis S., Faelli N., Begliatti E., Droghetti R., Tremolati E. et al. Role of atypical bacteria and azithromycin therapy for children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2005;24(5):438– 444. doi: 10.1097/01.inf.0000160949.99560.8d.

4. Abdulkerimov Kh.T., Garashchenko T.I., Koshel V.I., Ryazantsev S.V., Svistushkin V.M.; Ryazancev S.V. (ed.). Principles of etiopathogenetic therapy of acute sinusitis: guidelines. St Petersburg: Poliforum Grupp; 2014. 40 p. (In Russ.) Available at: https://files/sinus_.pdf.

5. Polyakova A.S., Bakradze M.D., Tatochenko V.K., Chashchina I.L. Bacterial infections of the upper respiratory tract: how to treat? Meditsinskiy sovet = Medical Council. 2018;(17):94–102. (In Russ.) doi: 10.21518/2079-701X-2018-17-94-102.

6. Munita J.M., Arias C.A. Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016;4(2). doi: 10.1128/microbiolspec.VMBF-0016-2015.

7. Ernst E. A systematic review of systematic reviews of homeopathy. Br J Clin Pharmacol. 2002;54(6):577–582. doi: 10.1046/j.1365-2125.2002.01699.x.

8. Goldacre B. Benefits and risks of homoeopathy. Lancet. 2007;370(9600):1672–1673. doi: 10.1016/S0140-6736(07)61706-1.

9. Koehler G. The Handbook of Homeopathy: Its Principles and Practice. Healing Arts Press; 1986. 240 p.

10. Orizola A.H., Vargas F. Efficacy of Traumeel S ointment versus diclofenac and placebo in the treatment of pain in professional athletes: a doubleblind randomized controlled trial. Biologicheskaya medicina = Biological Medicine. 2009;(1):14. (In Russ.) Available at: https://www.arnebia.ru/cgibin/download.cgi?id_dnl=1132.

11. Zell J., Connert W.D., Mau J., Feuerstake G. Behandlung von akuten Sprunggelenksdistorsionen: Doppelblindstudie zum Wirksamkeitsnachweis eines homöopathischen Salbenpräparats. Fortschr Med. 1988;106(5):96–100. Available at: https://www.heel-russia.ru/media/downloads_pdf/heel_medicines_ru_1/_______.pdf.

12. Burmeister Y., Cesnulevicius K., Goldman A.W., Lescheid D.W., Schultz M., Seilheimer B. Bioregulatory Systems Medicine Model. Biologische Heilmittel Heel GmbH; 2017. 86 p. Available at: https://www.bioregulatory-systemsmedicine.com/ru/whitepaper/%D0%BF%D0%BE%D0%B4%D1%80%D0%BE%D0%B1%D0%BD%D0%B5%D0%B5/bioregulatory-systems-medicinewhitepaper.

13. Goldman A.W., Burmeister Y., Cesnulevicius K., Herbert M., Kane M., Lescheid D. et al. Bioregulatory systems medicine: an innovative approach to integrating the science of molecular networks, inflammation, and systems biology with the patient’s autoregulatory capacity? Front Physiol. 2015;6:225. doi: 10.3389/fphys.2015.00225.

14. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell. 2010;140(6):771–776. doi: 10.1016/j.cell.2010.03.006.

15. Nathan C., Ding A. Nonresolving inflammation. Cell. 2010;140(6):871–882. doi: 10.1016/j.cell.2010.02.029.

16. Afanasev V.V., Zoryan E.V., Krasnikova T.V. An antihomotoxic approach to the treatment of inflammatory diseases of the salivary glands. Klinicheskaya stomatologiya = Clinical Dentistry. 2012;(1):16–18. (In Russ.) Available at: https://elibrary.ru/item.asp?id=22615917.

17. Žilinskas J., Žekonis J., Žekonis G., Šadzevičienė R., Sapragonienė M., Navickaitė J., Barzdžiukaitė I. Inhibition of peripheral blood neutrophil oxidative burst in periodontitis patients with a homeopathic medication Traumeel S. Med Sci Monit. 2011;17(5):CR284-91. doi: 10.12659/msm.881769.

18. Porozov S., Cahalon L., Weiser M., Branski D., Lider O., Oberbaum M. Inhibition of IL-1beta and TNF-alpha secretion from resting and activated human immunocytes by the homeopathic medication Traumeel S. Clin Dev Immunol. 2004;11(2):143–149. doi: 10.1080/10446670410001722203.

19. Oberbaum M., Spira R.M., Lukasiewicz E., Armon Y., Samuels N., Singer S.R. et al. Effect of Traumeel S on cytokine profile in a cecal ligation and puncture (CLP) sepsis model in rats. J Altern Complement Med. 2011;17(10):909–913. doi: 10.1089/acm.2011.0205.

20. Lussignoli S., Bertani S., Metelmann H., Bellavite P., Conforti A. Effect of Traumeel S, a homeopathic formulation, on blood-induced inflammation in rats. Complement Ther Med. 1999;7(4):225–230. doi: 10.1016/s0965-2299(99)80006-5.

21. Hazelen R. An integrative review of the evidence for the efficacy of the antihomotoxic drug Traumeel. RMZH = RMJ. 2017;(3):185–197. (In Russ.) Available at: https://www.rmj.ru/articles/zabolevaniya_kostno_myshechnoy_sistemy/Integrativnyy_obzor_dokazatelystv_effektivnosti_antigomotoksichnogo_preparata_Traumely/#ixzz6YrKbbFk3.

22. Müller-Löbnitz C., Göthel D. Review of the clinical efficacy of the multicomponent combination medication Traumeel and its components. Altern Ther Health Med. 2011;17(2):18–31. Available at: https://docplayer.net/14080865-The-multicomponent-combination-medication.html.

23. St Laurent G. 3rd, Seilheimer B., Tackett M., Zhou J., Shtokalo D., Vyatkin Y. et al. Deep Sequencing Transcriptome Analysis of Murine Wound Healing: Effects of a Multicomponent, Multitarget Natural Product Therapy-Tr14. Front Mol Biosci. 2017;4:57. doi: 10.3389/fmolb.2017.00057.

24. Schneider C., Schneider B., Hanisch J., van Haselen R. The role of a homoeopathic preparation compared with conventional therapy in the treatment of injuries: an observational cohort study. Complement Ther Med. 2008;16(1):22–27. doi: 10.1016/j.ctim.2007.04.004.

25. Schneider C. Traumeel – an emerging option to nonsteroidal anti-inflammatory drugs in the management of acute musculoskeletal injuries. Int J Gen Med. 2011;4:225–234. doi: 10.2147/IJGM.S16709.

26. Das R., Deshmukh J., Asif K., Sindhura H., Devarathanamma M.V., Jyothi L. Comparative evaluation of analgesic and anti-inflammatory efficacy of ibuprofen and traumeel after periodontal flap surgery: A randomized triple-blind clinical trial. J Indian Soc Periodontol. 2019;23(6):549–553. doi: 10.4103/jisp.jisp_85_19.

27. Ilnytskyĭ R.I. Immunological reactivity and correction of immunological disorders by biological medicines in patients with chronic obstructive pulmonary disease exacerbations. Likarska sprava = Medical Business. 2014;(7–8):22–27. (In Ukr.) Available at: https://liksprava.com/index.php/journal/issue/view/9/7-8-2014-FULL-PDF.

28. Oberbaum M., Yaniv I., Ben-Gal Y., Stein J., Ben-Zvi N., Freedman L.S., Branski D. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Cancer. 2001;92(3):684– 690. doi: 10.1002/1097-0142(20010801)92:33.0.co;2-#.

29. Palchun V.T., Gurov A.V., Dubovaya T.K., Ermolaev A.G. Histological examination of the palatine tonsils in chronic tonsillitis. Meditsinskiy sovet = Medical Council. 2019;(20):68–71. (In Russ.) doi: 10.21518/2079-701X-2019-20-68-71.

30. Clement W.A., Dempster J.H. Implementation by Scottish otolaryngologists of the Scottish Intercollegiate Guidelines Network document Management of Sore Throats and the Indications for Tonsillectomy: four years on. J Laryngol Otol. 2004;118(5):357–361. doi: 10.1258/002221504323086543.

31. Popovich S.V. Lymphomyosot – a bioregulatory approach in the treatment of childhood disease. Zdorove rebenka = Child health. 2015;(7):64–68. (In Russ.) Available at: http://www.mif-ua.com/archive/article/41885.

32. Serafino A., Sinibaldi Vallebona P., Andreola F., Zonfrillo M., Mercuri L., Federici M. et al. Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response. BMC Immunol. 2008;9:17. doi: 10.1186/1471-2172-9-17.

33. Keim A.P., Slis J.R., Mendez U., Stroup E.M., Burmeister Y., Tsolaki N. et al. The multicomponent medication lymphomyosot improves the outcome of experimental lymphedema. Lymphat Res Biol. 2013;11(2):81–92. doi: 10.1089/lrb.2012.0024.

34. Saeki H., Moore A.M., Brown M.J., Hwang S.T. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol. 1999;162(5):2472–2475. Available at: https://www.jimmunol.org/content/162/5/2472.long.

35. Jakubzick C.V., Randolph G.J., Henson P.M. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol. 2017;17(6):349–362. doi: 10.1038/nri.2017.28.

36. Vigl B., Aebischer D., Nitschké M., Iolyeva M., Röthlin T., Antsiferova O., Halin C. Tissue inflammation modulates gene expression of lymphatic endothelial cells and dendritic cell migration in a stimulus-dependent manner. Blood. 2011;118(1):205–215. doi: 10.1182/blood-2010-12-326447.

37. Wiley H.E., Gonzalez E.B., Maki W., Wu M.T., Hwang S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst. 2001;93(21):1638–1643. doi: 10.1093/jnci/93.21.1638.

38. Resolution of the Council of Experts of the National Medical Association of Otorhinolaryngologists on the problems of lymphopharyngeal ring pathology. Rossiiskaya otorinolaringologiya = Russian Otorhinolaryngology. 2020;19(1):127–130. (In Russ.) Available at: https://elibrary.ru/item.asp?id=42384540.